Ringing in the New Year!
Welcome 2024! But before we leave 2023 behind, this end-of-year newsletter features a recap of some of the outstanding and innovative work that our client companies are doing, and their successes along the way. We hope you enjoy sharing in their wins as much as we do.
This end-of year edition of the OBI & OTRADI newsletter also welcomes a returning client company, delivers a special thank you, and lists some awesome upcoming events. Please feel free to share.
We hope you have a peaceful and prosperous 2024.
Client Company Wins in 2023
- Joined the OBI in June, 2023.
- In September, 2023, AirOmatix was Runner-Up in the Cascadia CleanTech Accelerator Pitch Competition. Their pitch focused on how their oxygen concentrating technology could reduce global greenhouse gas emissions by eliminating the need for transporting metal cylinders of oxygen.
- They received the Judge’s Award in the Early Stage Startup category of the Oregon Bioscience Association’s 2023 Innovation Showcase. Their pitch touted the benefits of AirOmatix’s small, quiet, high-flow oxygen concentrating technology over the larger, louder, and lower-flow products on the market.
- CANX hired Felix Cohen and Killian Anreise to their staff.
- They are developing therapeutics to address iron-related health conditions such as iron overload disease and certain forms of cancer which depend on iron for their growth.
- Caravel won the Tufts University $100k Startup Competition and were semi-finalists for the MIT Climate & Energy Prize in Spring 2023.
- Caravel Bio joined the OBI in August, 2023 with an office and a lab.
- They hired Arushi Kalia as an Engineering Research Associate. Arushi is working on strain engineering and bioprocess development.
- Caravel has joined the SQM Lithium Ventures Accelerator. The Caravel team will be exploring applications of their protein engineering platform in lithium mining, aided by scientists and engineers from SQM. SQM, headquartered in Chile, is a global leader in lithium mining and chemical production.
- They were one of 6 startups selected for the Greentown Go Make with Shell 2023 Program. The Caravel team is proud to announce the company was selected from over 100 applicant companies from around the world to work with Greentown Labs and Shell to develop products for CO2 capture and utilization. As a part of the program, Caravel received $15,000 in non-dilutive funding and will work with mentors and subject matter experts from the Greentown Labs community and Shell to advance Caravel’s Catalytic Biotechnology platform.
- In December, Caravel closed their pre-seed round with a total raise of $1.012M in dilutive and non-dilutive funding.
- Received an investment from AGA’s GI Opportunity Fund. Read Business Wire press release here.
- EndoSound Inc., a privately held medical device company developing an endoscopic ultrasound platform to diagnose and treat diseases of the gastrointestinal tract, today announced the initial closing of its Series A round financing.
- The round is being led by GEO Medtech Venture Fund, a leading healthcare venture capital firm that invests in transformative medical technology, and health solutions companies seeking to improve clinical outcomes, enhance quality of life, and drive efficiency of healthcare delivery.
- The financing will support EndoSound’s ongoing research and development and preparations for commercial launch. The EndoSound Vision System (EVS) is designed to eliminate the financial burden of expanding access to care for patients who require an endoscopic ultrasound (EUS) procedure. By attaching the EVS Transducer to a standard upper endoscope found in all hospitals and GI surgery centers, this critical technology becomes available and affordable in more areas of care.
- They successfully closed their series A round of funding, raising $5M, which closed in October.
- EndoSound is now pursuing a Series B round with the goal of raising an additional $12M in funding in anticipation (pending regulatory clearance) of first sales in 1st Q 2024.
- NEW! EndoSound is proud to announce the FDA 510(k) clearance of our EndoSound Vision System® (EVS®) on December 27, 2023. This novel and innovative device enables endoscopists to convert upper GI endoscopes into an endoscopic ultrasound (EUS) device. The EVS converts flexible endoscopes from any of the leading manufacturers into a fully functional EUS system providing high quality imaging consistent with today’s leading technology. Moreover, the EVS is significantly less expensive compared to conventional EUS systems.
- Joined the OBI in June, 2023 and moved into a lab in OBI’s recently built-out suite.
- ESG Brands was awarded acceptance into the Germany supported Global Entrepreneurship Centre (GEC) for scaling start-ups which includes €25,000 in-kind contribution and 10 weeks of supported programming to facilitate growth. The GEC scales innovative companies with sustainable technologies, processes, and business models for impact.
- Raised $200,000 out of the $500,000 goal for 2nd round funding. Targeting to close before the end of July to support scale-up and further development.
- Accomplished successful repeatability trial for their accelerated degumming process.
- Accomplished 90/10 blended silver: a precursor to yarn spinning, and a key milestone in the development process.
- Selected for German-funded impact accelerator, Global Entrepreneurship Centre (GEC) Summer Cohort. 1 of 15 global start-ups chosen by GEC to accelerate scale and funding in order to unlock global impact.
- Successfully online and operating out of OBI Lab space kicking off local Portland IP development at the intersection of farms x chemistry x fashion.
- Ideaship has successfully completed a $100,000 patent equity investment in ESG Brands. Ideaship has been instrumental in supporting their intellectual property (IP) applications and will continue to play a pivotal role in shaping their IP strategy, thereby establishing a robust foundation to facilitate their growth backed by venture capital.
- Secured first customer within the industrial textiles space.
- Successfully consolidated the fiber supply chain to afford faster processing times and expedite the scale-up of their Tempo™ technology.
- ESG Brands was a finalist at Bend Venture Conference in the Impact Competition.
- Recognition for Revitalizing Portland’s Start-up Scene: they’ve gained recognition as a key contributor to the resurgence of the Portland start-up landscape — scaling the world’s next natural fiber to fight climate change, and enable the textile industry to meet climate targets. Check out their feature in the Business Journal: Read more.
- Cover Story and 2-Page Spread: Thrilled to share that their success has been showcased prominently in Portland Business Journal showcasing 2 out of their 5 teammates! They’ve secured a headline cover story and an extensive 2-page spread, amplifying impact and reach.
- Successful Completion of First Scale-Up Trial: Celebrating a major milestone, they have completed ESG’s first scale-up trial with a prominent factory group, demonstrating capability and confidence from within the industry.
- Innovation Highlight: Potable Water MVP from Process Waste: Thrilled to announce the successful creation of their first Minimum Viable Product (MVP): potable water derived from process waste. This breakthrough not only showcases their commitment to sustainable innovation but also highlights the circularity capabilities within their process. Additionally, it demonstrates their ability to create potable water from ESG’s natural fiber banana plant feedstock—an achievement not replicated with any other natural fiber.
- ESG Brands was featured in the “13 Startups to Watch in 2024” special report in the December 15 issue of the Portland Business Journal.
- BANEX™ Yarn! ESG Brands ended the year with their first yarn trial, and it was successful! Immediately after and in an industrial setting, further improvements were seen with impressive results. Next up: more yarn will be run and textile made. For a preview or interest in supporting the growth, please contact ESG Brands.
- Naturally Fire-Retardant Nonwovens! The team tested their most recent nonwoven product and received impressive results: with no fire retardant additives their first nonwoven product is self-extinguishing well under the FMVSS 302 test standard (FMVSS -Federal Motor Vehicle safety standard, flammability test for interior materials on vehicles).
- The TAO awards committee nominated Gamma Diagnostics as a finalist for the Technology Company of the Year, Emerging category. The 2023 Oregon Technology Awards was held on May 16, 2023.
- They published a 103-patient COVID-19 study showing that their diagnostic test for gamma prime fibrinogen (GPF) can differentiate between mild/moderately ill patients, severely ill patients, and non-patients better than six other widely-used diagnostic tests. The paper is published here.
- They are thrilled to announce an exclusive distribution agreement and the SAHPRA approval of GammaCoeur™ CVD Risk ELISA Test System with Afri Grow (Pty) Ltd. For more information, see the press release.
- Gamma Diagnostics was awarded a Phase I STTR of $277,710 by the NIH to develop antisense oligonucleotides to regulate GPF levels.
- Major Successes
- Gazelle, Hemex Health’s diagnostics platform, was installed in a blood bank of Rotary Blood Bank near Delhi. This is a new application for Gazelle to test donated blood for beta thalassemia.
- They obtained the first government tender for the National Sickle Cell Anemia Elimination Program from the state of Odisha, one of the 17 states under the program. The Program aims to screen 70 million people and to eliminate sickle cell disease in India by 2047.
- Gazelle made its debut in Vietnam. Their distributor in Vietnam, Biomedical Vietnam, collaborated with Nghia Lo Regional General Hospital for beta thalassemia screening. Biomedical Vietnam conducted screenings with Gazelle for 48 schoolchildren and individuals of marriage age. The debut was an exciting start for the distributor to showcase Gazelle to subject experts ahead of the nationwide rollout.
- Product Development
- Hemex is collaborating with MUJN Diagnostics Inc., to develop a diagnostics system that can be used to support patients being treated with alternative therapies for brain health.
- CEO, Patti White, and Gerrit van Roekel, VP of Business Development, traveled to Ghana to to get input from clinical partners at Korle Bu Teaching Hospital on their new, easy-to-use cartridge that will simplify sample preparation for their sickle cell test.
- New VP of Finance
- Josh Cyphers has joined Hemex Health as the new VP of Finance at Hemex Health. Josh has held senior roles in both large and startup companies and brings a passion for making a positive social impact.
- Awards and Recognition
- The company was featured on Business Oregon’s Innovation landing page, under “Oregon Business Solves Challenging Global Disease Testing Issue.”
- Patti White, CEO of Hemex Health, received an award from Alliance Indus and Fiona Ma (CA State Treasurer) for the strong partnerships with Indian businesses that brought Gazelle, an innovative decentralized point-of-need testing solution, to the market. The award also recognizes Hemex’s significant contribution to the Make in India initiative.
- Hemex Health won a 3-year $3M NIH grant from the NHLBI to commercialize their Hb Variant test for the US market. Read the press release to learn more about the grant.
- Hemex Health participated in the 25th MTAR Labcon 2023 Conference in Alibaug, India where sickle cell disease is highly prevalent. It was a valuable chance for the company to interact with delegates from the Raigad region and to gather feedback from those delegates on Gazelle.
- Patti White, CEO and co-founder of Hemex Health, was asked to speak at the IFC (International Finance Corporation) Global Private Health Conference in Cape Town, South Africa. White talked about the innovation that small companies can bring to global health problems and the potential market opportunities.
- Peter Galen, Chief Innovation Officer, served as a panelist at Davos Worldwide Summer 2023, a conference focused on designing and implementing global impact initiatives. During the panel, Galen discussed the crucial role that healthcare companies play in eradicating Sickle Cell Disease.
- Pinecrest Healthcare Ltd, Hemex Health’s distributor in Nigeria, presented Gazelle at the Nigeria Society for Haematology and Blood Transfusion conference, outlining Gazelle’s role in facilitating sickle cell disease (SCD) testing in the country to subject matter experts.
- Peter Galen, Hemex Health’s Chief Innovation Officer, was honored with an invitation to speak at the American Medical Device Summit. Galen ignited discussions on propelling innovation and prioritizing patient-centricity in the global medical device landscape.
- Patti White, CEO of Hemex Health, participated in the 18th Annual Academy of Sickle Cell and Thalassaemia Conference (ASCAT) in London. Throughout the conference, Gazelle garnered significant interest from KOLs and field experts due to its capability to facilitate affordable and accessible SCD diagnosis in low-resource areas.
- Hemex Health participated in the 64th Annual Conference of the Indian Society of Haematology & Blood Transfusion, a prominent event in the field of hematology. They were invited to present Gazelle during the lecture on “Next-Generation Integrated, Affordable Point-of-Care Solution for Haemoglobinopathy.” This provided them with a valuable opportunity to engage with hematologists and demonstrate the capabilities of Gazelle.
- Intel Corp. has asked HTI to benchmark their new Xeon platform with CryoDiscovery™, HTI’s AI-based automation platform for cryo-EM image acquisition and processing.
- Dr. Gabriella Kiss joined the HTI Advisory Board as Senior Advisor. Dr. Kiss brings extensive experience in life science and Business Development to HTI.
- A leading cryo-EM instrument vendor has provided an LOI for integrating CryoDiscovery™, HTI’s AI-based automation platform for cryo-EM image acquisition and processing, with their product.
- The Pacific Northwest Computing Center (PNCC) and OHSU have approved for CryoDiscovery™ field testing.
- ADRx, a drug discovery vendor, has initiated another project for cryo-EM analysis.
- HTI is excited to announce that Dr. Santi Adavani is joining HTI Advisory Board as Senior Advisor. Dr. Adavani brings extensive experience in AI/ML and software product development to HTI. Read full press release here.
- Attended BIO23 as a co-sponsor of the Oregon Bioscience Association‘s Oregon Pavilion. BIO2023, BIO International Convention | BIO, is the premier international conference with over 17K attendees representing biotech, pharma and investment companies. Meetings set with over 30+ partners to advance cryo-EM service and software business.
- Successfully finished early CryoDiscovery™ testing at OHSU/PNCC.
- Successfully submitted the Phase 2 matching grant final report to Business Oregon.
- Submitted application, per NSF invitation, for TCEP, Technology Enhancement for Commercial Partnerships (TECP) supplemental funding.
- Signed Cryo-EM MSA with BASF.
- Advanced partnership project with ADRx toward full completion into 3D model building stage.
- Successfully delivered CryoDiscovery™ presentation at ACA23 (American Crystallographic Association) on July 9 with over 200 attendees.
- Signed MSA (master services agreement) for cryo-EM nanoparticles analysis with path.org, the non-profit funded by the Gates Foundation in Seattle.
- Had over 30 partner meetings at BIO 2023 which resulted in few good sales leads.
- Successfully presented CryoFast™ – an AI-based platform for automating cryo-EM image collection at ACA’23 and M&M’23 – two international microscopy conferences. Met with industry partners and received strong product support from the cryo-EM community.
- Received NSF Phase II supplemental funding to integrate CryoFast™ with the leading cryo-EM camera vendor’s data collection application.
- Welcome Leo Crowder and welcome back Ryan Dehart – two great additions to our development team.
- Signed MSA with a major European chemicals company for cryo-EM structure determination services for agricultural crop protection chemicals project.
- Embarked on a new project using cryo-EM to assess Lipid Nanoparticles with mRNA for a leading non-profit working on scaling Coronavirus vaccine production to developing lower-income countries.
- Due to strong demand for structure-determination services, HTI signed agreement with Kansas University Medical School as the 2nd cryo-EM imaging partner site. The first partner site is U. of Washington cryo-EM center.
- OSU selected HTI for their M.S. AI Capstone project.
- Signed agreement with Miller Nash as HTI legal counsel.
- CryoFast™ alpha testing at OHSU in its final stage with results to be shared with our industry/pharma partners.
- Keliomics was a finalist at the 2023 Oregon Technology Awards which was held on May 16, 2023.
- They were also a finalist at Angel Oregon Life & Bioscience in May at Amaterra Winery.
- They kicked off their OncoScreen pilot study in partnership with Legacy Health and enrolled their first patient. This marks the first time an intact breast tumor has been cultured in breast adipose tissue from the same patient.
- Keliomics won a $100,000 investment from ONAMI and a $100,000 investment from Ideaship at the Angel Oregon Life & Bioscience finale in May.
- Keliomics was featured in the Portland Business Journal for their novel approach to targeted cancer treatment.
- New Hire: Shane Sweeney, Lab Technician.
- New Advisory Board Member: Andreas Penk, Former President of Pfizer China; Pfizer Oncology EMEA.
- Capital raised in October: $400k in seed round convertible notes.
- Projects Completed: McDonnell Lab – Duke, Olzmann Lab – UC Berkeley, Scherer Lab – UT Southwestern.
- Keliomics was featured in the “13 Startups to Watch in 2024” special report in the December 15 issue of the Portland Business Journal.
- OmnEcoil received FDA approval to initiate a clinical trial of their device for simultaneous MRI imaging and biopsying of the prostate.
- They have also subsequently received IRB approval from OHSU for this trial and expect to initiate patient recruitment in the near future.
- PDX Pharma received continued Phase II SBIR funding from the National Cancer Institute (NCI) to support a novel lung cancer treatment, ARAC-02. Read more here.
- They have received a fast-track SBIR award from the National Cancer Institute, which focuses on development of a drug candidate named PETTRA (PLK1 and EGFR Targeted Therapy and Radiation sensitizer) for lung cancer treatment. The budget is about $2.4M over 3 years. Read more here.
- They have been selected as one of six semi-finalists for the 2023 AIM-HI Women’s Venture Competition.
- They were granted a new US patent (11,679,082) on nanoparticle co-delivering broad ranges of mitotic kinase inhibitors and immune checkpoint inhibitors.
- Their EU patent application (16765662.8) on the core Pdx-NP delivery platform received the notice of allowance.
- They received a fundable score on their pending Commercialization Readiness Pilot (CRP) grant application at the NCI. The budget is about $250,000 over 2 years.
- Their drug candidate, ARAC-02, was selected into the Nanotechnology Characterization Lab (NCL)’s collaborative program funded by the NCI.
- They published a review article at SMALL (impact factor 13.3) on the topic of ‘Nanotechnology Applications in Breast Cancer Immunotherapy,’ in a special issue of Nanomedicine for Women’s Health.’ Read more here.
- ProMedix Inc. has been awarded a U.S. National Science Foundation (NSF) Small Business Technology Transfer (STTR) grant for $250,000.00 to conduct research and development (R&D) work on improving outcomes from sepsis through active digital monitoring of peripheral blood flow.
- They were selected to advance to the final round of Creative Destruction Labs.
- ProMedix was the winner of Oregon Entrepreneurs Network‘s entrepreneurial education and angel investment program Angel Oregon Life & Bioscience in May! They received the $185,000 AOBIO angel investment, as well as an additional $75,000 investment from ONAMI.
- They published an important paper in the American Journal of Emergency Medicine, entitled Evaluation of electronic measurement of capillary refill for Sepsis screening at ED triage.
- They were invited to attend the Creative Destruction Lab Super Session in Toronto, Canada after graduating from their Vancouver, Canada accelerator program.
- ProMedix was featured on page 13 of the OHSU Innovates 2023 Impact Report. Read the report here.
- Rewire Neuro is now Rewire AI. This change comes as part of a re-energized effort from Rewire to more fully embrace their position as a premier AI company with technology that has application in more markets than just
- CSciO, Kristy Lawton, was an invited speaker on OBA’s Bio On The Rocks Artificial Intelligence panel.
- CEO, John Harkness, was an invited speaker on TAO’s Generative AI in Healthcare panel.
- John Harkness was honored to meeting with Senator Ron Wyden and Business Oregon to discuss Oregon’s role in the international marketplace and how we can support trade from Oregon businesses, like Rewire AI.
- Rewire launched the next generation of their image analysis platform, called Polygon AI. This milestone marks the addition of new AI capabilities, advanced multiplex analysis, and 3D image processing.
- They were awarded a Phase I SBIR from NIH NIGMS to develop their patented “AutoML” platform for automated generation of custom AI models.
- Rewire AI was selected as a finalist to pitch in the Life Science Washington Institute “Startup Showcase” and was selected as an NIH SBIR funded startup to pitch and present in the NIH booth at the 2023 HLTH conference in Las Vegas. Additionally, they were invited to pitch at the MedInvest AI conference in Silicon Valley.
- John Harkness was invited to speak with Senator Ron Wyden in the TAO AI Town Hall executive session.
- They secured an additional contract to provide AI capabilities to their largest device partner to-date.
- John Harkness was invited to speak on the “If I Knew Now” panel about challenges faced as a startup founder at the Oregon Bioscience Association Biotech Summit.
- John was also interviewed on the Darwoft “Dare” podcast about Rewire’s efforts to innovate in the biomedical AI space.
- They welcomed Samantha Munoz to their team.
- Senju’s manuscript has been accepted but still in press. They found a cysteine protease, calpain, specific cleaved alpha-spectrin in soft and hard drusen from human donors. This suggests calpain=induced proteolysis participates photoreceptors and RPE cell degeneration during aging and AMD.
- Sonivate Medical, Inc. was invited to SEASON Aesthetic Conference held at George Washington University, Washington, DC in April 2023. This was a gathering of key opinion leaders in dermatology and plastic surgery to discuss the application of ultrasound for cosmetic procedures e.g., facial fillers.
- Besides discussions, there was hands-on using a cadaver lab for injections and several stations for the participants to rotate through including Sonivate’s next generation product. Sonivate was one of a very few companies invited to present at this research oriented, technical symposium. The presentation is titled SonicEye Finger Probe Ultrasound System – Meeting Customer Needs through Disciplined Research.
- They released a new product this year called HEMIGARD Interlock, which allows surgical incision closure/support without sutures. A proprietary hook and loop technology from 3M has been incorporated into their existing HEMIGARD design and allows for considerable tension relief at the incision healing edge. This protects skin edge blood flow and optimizes healing and scarring outcomes.
- Their Classic HEMIGARD ASRD (Adhesive Suture Retention Device) is used now in over 230 hospitals in the USA and helps surgeons close high tension or at risk wounds. They envision HEMIGARD Interlock for gentler support in elective surgeries such as joint replacement, bunion correction, cosmetic surgery and other.
- Q1 2023 was their first profitable quarter and hope to build on this momentum and continue to their goal of being self-funding through sales revenue.
- Trace Biosciences welcomed four new team members:
- Nathan McMahon, Ph.D. – Clinical Project Manager
- Bryce Timm, Ph.D. – Staff Scientist
- Grace Hubbel, Ph.D. – Staff Scientist
- Ge Huang, Ph.D. – Senior Research Associate
- Trace Biosciences was a finalist at Angel Oregon Life & Bioscience held in May at Amaterra Winery.
- They won a $125,000 investment from ONAMI at the Angel Oregon Life & Bioscience finale.
- Received an investment from the Elevate Innovation Gap Fund.
- Received a $4.1M SBIR award from ARPA-H covering development and clinical translation of their technology for nerve-specific imaging intraoperatively.
- Completed two pre-IND meetings with the FDA and preparing IND package for first-in-human trials spring 2024.
- Presented at Intraoperative Imaging Society meeting in Deer Valley, Utah.
- Won judge’s choice best pitch at OBA Innovation Showcase in the Later Stage category.
- Trace Biosciences was featured on page 8 of the OHSU Innovates 2023 Impact Report. Read the report here.
Vaginal Biome Science
- Joined the OBI in April, 2023 with an office in our brand new office suite. They expanded into two additional office spaces in January, 2024.
- From their website: Together with our strong alliance of partners, we are broadening and accelerating groundbreaking studies into the vaginal biome, pioneering new understanding of the role of the biome as a determinant of vaginal and overall health, and developing new products, solutions, and protocols – redefining decades-old and tired approaches to women’s health.
- Veana received a $50,000 competitive matching grant from Business Oregon to leverage their Phase 1 SBIR grant.
- Pleased to announce publication of a proof-of-concept study demonstrating that its oral drug, a-TEA-LS (aka VIMO) improves the anti-tumor efficacy of immune checkpoint blockade antibody in pre-clinical models of triple negative breast cancer.
- Veana welcomed Patricia Beckman as CEO.
- Vivivi Medical joined the incubator in December 2023.
- Founded in Houston, Texas, they are looking forward to making Oregon their headquarters. Vivivi Medical is developing a permanent solution that reverses Benign Prostate Hyperplasia (BPH) through a robotic/laparoscopic procedure.
OBI Alumni Updates
- Absci recently announced a collaboration with AstraZeneca to deliver an AI-designed antibody as a potential new cancer treatment. Read about it in the Portland Business Journal.
- They’ve also recently partnered with PrecisionLife to work together to discover and develop a shared pipeline of biotherapeutics.
- Erik Tucker, PhD, founder and CEO of Aronora received a National Academy of Inventors Fellow award at the National Academy of Inventors Annual Winter Warmer: Celebrating Innovation Excellence in Oregon.
- Aronora recently raised a funding round with investment from New York Blood Center’s venture fund to support their anti-coagulant drug development.
- Endocrine Society announced that their Outstanding Innovation Award will recognize Sparrow’s work on a potential new medicine for patients with Cushing’s syndrome, autonomous cortisol secretion, or who rely on long-term glucocorticoid (e.g., prednisone) to control autoimmune diseases and other conditions. Read about the 2024 Laureate Recipients here.
- First patient has been dosed in Sparrow’s Phase 2 clinical trial for autonomous cortisol secretion treatment.
- Dr. David Katz, CSO, was featured on the “If We Knew Now” panel discussion at the Oregon Bioscience Association Biotech Summit.
Synergic Medical Technologies
- Synergic has initiated a clinical trial for the vibrotactile treatment they developed for people with Parkinson’s. The study is posted on clinicaltrials.gov (NCT05881460) and their partners at OHSU will start enrolling people soon. They expect the data from this study to enable them to submit to FDA for market clearance.
Congratulations on your hard work and successful endeavors! You’re creating wonderful innovations for healthcare.
Captis Biotechnology Rejoins the OBI
Welcome back to Captis Biotechnology, who rejoined the OBI this month with space in our first floor north wing. Captis has created targeted biosensors and bioimaging agents for cancer and other diseases.
We are pleased to have them return to the incubator!
Thank You for Your Continued Support!
OBI is gearing up for some excellent free entrepreneurial programming this year, designed to support startups of all stages of development across the state. We have monthly Lunch & Learns on all kinds of interesting topics geared toward the life science community, regular Happy Hour networking events, and a robust BioMentoring program.
We are so pleased to be able to bring you these valuable programs and events, and we thank you for your support over the past 10 years since our incubator opened. To help support our upcoming educational offerings, each of our programs has sponsorship opportunities available. We also have Platinum, Gold, and Silver corporate sponsorship packages for a year-long impact.
To continue your support of OBI’s programming with a tax-deductible sponsorship, please take a look at our Sponsorship Kit and contact Rene Miller for sponsorship or questions.
OBI Accelerate Happy Hour Networking
January 11 | 5:30-7:00 PM
OBI Event Space, Portland
Free but nearly full! Register here
OBI Lunch & Learn: Bootstrapping Social
January 17 | 12:00-1:00 PM
Free – register here
America’s Seed Fund Week
and Virtual Road Tour 2024
January 23 and 24
More information here
OHSU Innovates Speaker Series:
Securing Non-Dilutive Funding for Innovative Businesses
January 24 | 9:00-10:00 AM
Free – learn more and register
ITHS Biomedical Innovation Fireside Chat Series
Jan 25, Feb 8 & 22, Mar 7, Apr 4 & 18, May 2 | 2:00-3:00 PM
Free – register here
Built Oregon Presents PitchBlack 2024
February 7 | 5:30 PM
The Patricia Reser Center for the Arts, Beaverton